Statistically significant reductions in lesion surface volume and absolute change in average height for paired lesions were observed with the use of orally administered everolimus as a treatment for neurofibromatosis type 1-associated cutaneous neurofibromas

Dramatic reductions in the size of three large plexiform neurofibromas with a cutaneous component were also observed by measurement of maximum circumference or magnetic resonance imaging-based volumetric analysis

Adverse events were common, but no serious adverse events occurred